✦ LIBER ✦

253 Screening for PIK3CA, RAS, and RAF mutations in trials with PI3K/AKT/mTOR signaling pathway inhibitors

✍ Scribed by F. Janku; A.M. Tsimberidou; I. Garrido-Laguna; D.S. Hong; A.M. Naing; G.S. Falchook; S. Fu; R. Luthra; X. Wang; R. Kurzrock

Book ID: 119602935
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 45 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)71959-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PIK3CA Mutation H1047R Is Associated wit

PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials

✍ Janku, F.; Wheler, J. J.; Naing, A.; Falchook, G. S.; Hong, D. S.; Stepanek, V. 📂 Article 📅 2012 🏛 American Association for Cancer Research 🌐 English ⚖ 494 KB

PI3K/AKT/mTOR Inhibitors in Patients Wit

PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies Harboring PIK3CA Mutations

✍ Janku, F.; Wheler, J. J.; Westin, S. N.; Moulder, S. L.; Naing, A.; Tsimberidou, 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 257 KB

PIK3CA Mutations in Patients with Advanc

PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors

✍ Janku, F.; Tsimberidou, A. M.; Garrido-Laguna, I.; Wang, X.; Luthra, R.; Hong, D 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 646 KB

Defining optimal combinations of PI3K/Ak

Defining optimal combinations of PI3K/Akt/mTOR and Ras/Raf/MAPK pathway inhibitors for use in endometrial cancer

✍ Isani, S.S.; Rodriguez-Gabin, A.G.; Goldberg, G.L.; Horwitz, S.B.; McDaid, H.M. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Therapeutic resistance resulting from mu

Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways

✍ James A. McCubrey; Linda S. Steelman; C. Ruth Kempf; William H. Chappell; Stephe 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 869 KB

## Abstract Chemotherapy remains a commonly used therapeutic approach for many cancers. Indeed chemotherapy is relatively effective for treatment of certain cancers and it may be the only therapy (besides radiotherapy) that is appropriate for certain cancers. However, a common problem with chemothe

A detailed immunohistochemical analysis

A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: Correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features

✍ Levidou, Georgia 📂 Article 📅 2013 🏛 Spandidos Publications Ltd 🌐 English ⚖ 941 KB